You are viewing: France AI in Oncology Market analysis
Part of: AI in Oncology Market (Global)

The France AI in Oncology Market was valued at $133.1 Million in 2024 and projected to reach to $675.1 Million by 2029, representing a compound annual growth rate of 31.1%. France's AI in Oncology market is positioned for exceptional growth through 2029, driven by substantial investments in healthcare digitalization and the country's commitment to precision medicine.

France AI in Oncology Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

France AI in Oncology Market Trends and Insights

  • This robust growth trajectory reflects France's commitment to integrating artificial intelligence into cancer diagnosis, treatment planning, and patient management across its healthcare system.
  • France is leveraging AI technologies to enhance precision oncology, improve clinical outcomes, and optimize resource allocation within its centralized healthcare infrastructure. The French market benefits from strong government support for digital health innovation, substantial investment in research institutions, and collaboration between academic medical centers and technology providers.
  • France's regulatory environment and emphasis on evidence-based medicine are driving adoption of AI-powered diagnostic imaging, predictive analytics, and treatment recommendation systems.
  • By 2029, France is expected to establish itself as a leading European hub for AI-enabled oncology solutions, with widespread integration across major cancer centers and regional hospitals..

Key Market Statistics

  • CAGR (2024-2029) 31.1% CAGR
  • Market Size, 2024 ~USD 133.1 Million
  • Forecast, 2029 ~USD 675.1 Million
  • Country France

France AI in Oncology Market Overview

Rapid Market Expansion :

France's AI in Oncology market is growing at 31.1% CAGR, outpacing the global average of 29.4%, demonstrating strong domestic adoption and investment in cancer care innovation.

Significant Revenue Growth :

Market valuation is projected to surge from $133.1 million in 2024 to $675.1 million by 2029, representing a five-fold increase driven by healthcare system modernization and precision medicine initiatives.

Healthcare System Integration :

France's centralized healthcare infrastructure and government support for digital health transformation are accelerating AI adoption in oncology departments across public and private hospitals.

Precision Oncology Focus :

French healthcare providers are increasingly deploying AI for diagnostic imaging analysis, treatment planning optimization, and personalized patient management in cancer care.

France AI in Oncology Market Dynamics

  • The French government's support for AI integration in the healthcare sector, combined with strong pharmaceutical and medical device industries, creates a favorable environment for market expansion.
  • Healthcare institutions are increasingly adopting AI solutions for improved diagnostic accuracy and treatment outcomes. The market will be further propelled by collaborations between French research institutions, hospitals, and technology companies developing innovative oncology AI applications.
  • Regulatory frameworks supporting medical AI adoption and reimbursement policies for AI-driven diagnostics will enhance market penetration.
  • France's aging population and rising cancer incidence rates underscore the critical need for advanced AI-enabled oncology solutions, positioning the country as a key growth market in European healthcare innovation..

Related Ecosystem

Healthcare Analytics

Top Technologies
  • Machine Learning
  • Natural Language Processing (NLP)
  • Blood Pressure Monitors
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
Top Companies
  • Oracle Corporation
  • PHILIPS HEALTHCARE
  • Siemens healthineers
  • Zensar Technologies Limited
  • EPIC SYSTEMS CORPORATION

    Healthcare It

    Top Technologies
    • Computed Tomography (CT)
    • Machine Learning
    • Magnetic Resonance Imaging (MRI)
    • Natural Language Processing (NLP)
    • Predictive Analytics
    Top Companies
    • CERNER CORPORATION
    • PHILIPS HEALTHCARE
    • Oracle Corporation
    • GE HealthCare Technologies Inc.
    • Siemens healthineers

      Key Takeaways

      • France's AI in Oncology market is projected to grow from $133.1M (2024) to $675.1M (2029), representing a 31.1% CAGR.
      • France's centralized healthcare system and government digital health initiatives are accelerating AI adoption in cancer care.
      • France is positioning itself as a European leader in precision oncology through AI-driven diagnostic and treatment technologies.
      • Strong collaboration between French academic institutions and technology vendors is driving innovation and market expansion in France.

      AI in Oncology Market Report Scope

      Report Metric Details
      Base Year 2024
      Fastest Growing Segment DEEP LEARNING (Type)
      Forecast Period 2024-2029
      Growth Rate CAGR of 29.4% from 2024 to 2029
      Largest Segment SOLID TUMORS (Cancer Type)
      Market Size Base Year (Billions) ~USD 2.45 (2024)
      Revenue Forecast (Billions) ~USD 8.9 (2029)
      Segments Covered Technology, Type, Application, Cancer Type, End User, Player Type, Deployment Model

      France AI in Oncology Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Technology

      • Computer Vision
      • Context-Aware Processing & Computing
      • Image Analysis
      • Machine Learning
      • Natural Language Processing
      • Natural Language Processing (Nlp)

      By Type

      • Adaptive Trial Design & Monitoring
      • AI-Guided Drug Delivery
      • Brain Tumors
      • Breast Cancer
      • Candidate Selection & Validation
      • Chemotherapy
      • Clinical Trial Optimization
      • Colorectal Cancer
      • Combination & Dose Optimization
      • Computed Tomography
      • Computed Tomography (Ct)
      • Deep Learning
      • Digital Pathology & Histopathology
      • Genetic Risk Prediction
      • Hit Identification & Prioritization
      • Hit-To-Lead Identification/Lead Generation
      • Hospitals & Clinics
      • Imaging & Radiology
      • Immunotherapy
      • Intraoperative Guidance & Robotics
      • Intraoperative Guidance And Robotics
      • Laboratories & Diagnostic Centers
      • Lead Optimization
      • Leukemia
      • Liquid Biopsy & Biomarker Detection
      • Long-Term Prediction
      • Lung Cancer
      • Lymphoma
      • Magnetic Resonance Imaging (Mri)
      • Mammography
      • Mental Health & Support Systems
      • Multiple Myeloma
      • Nuclear Imaging
      • Other Healthcare Providers
      • Other Hematologic Malignancies
      • Other Hematological Malignancies
      • Other Imaging Modalities
      • Other Machine Learning Technologies
      • Other Solid Tumors
      • Other Tumors
      • Others Healthcare Providers
      • Patient Education & Empowerment
      • Personalized Treatment Planning
      • Postoperative Analysis & Recovery
      • Precision Medicine & Genomic Analysis
      • Preclinical Testing
      • Predictive Modeling For Human Trials
      • Predictive Modelling For Human Trials
      • Predictive Models For Treatment Response
      • Preoperative Imaging & 3D Modeling
      • Preoperative Imaging And 3D Modeling
      • Prostate Cancer
      • Radiation Therapy
      • Radiomics & Radiogenomics
      • Radiomics And Radiogenomics
      • Recurrence Monitoring
      • Reinforcement Learning
      • Remote Patient Monitoring
      • Specialty Centers
      • Supervised Learning
      • Surgical Planning & Assistance
      • Symptom Management & Virtual Assistance
      • Target Identification & Validation
      • Targeted Therapy
      • Treatment Recommendation Systems
      • Ultrasound
      • Unsupervised Learning
      • X-Ray Imaging

      By Application

      • Data Management & Analytics
      • Diagnosis & Early Detection
      • Drug Development
      • Drug Discovery
      • Other Applications
      • Patient Engagement & Remote Monitoring
      • Post Treatment Surveillance & Survivorship Care
      • Post-Treatment Surveillance & Survivorship Care
      • Treatment Planning & Personalization

      By Cancer Type

      • Hematologic Malignancies
      • Hematological Malignancies
      • Other Cancer Types
      • Other Cancers
      • Others Cancer Types
      • Solid Tumors

      By End User

      • Academic & Research Institutions
      • Government & Regulatory Agencies
      • Healthcare Payers
      • Healthcare Providers
      • Medical Device/ Equipment Companies
      • Medical Device/Equipment Companies
      • Other End Users
      • Pharmaceutical & Biotechnology Companies

      By Player Type

      • Business Process Service Providers
      • Integrated Suite/Platform Providers
      • Niche/Point Solution Providers
      • Technology Providers

      By Deployment Model

      • Cloud-Based Model
      • Hybrid Model
      • On-Premises Model

      FRANCE: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030

      Segment202220232024202520262027202820292030CAGR (%)
      ACADEMIC & RESEARCH INSTITUTIONS8.0310.7813.9318.0723.530.6640.1352.6969.4130.68
      GOVERNMENT & REGULATORY AGENCIES3.184.215.366.868.811.3114.618.924.5528.85
      HEALTHCARE PAYERS1.962.623.374.355.647.339.5512.4916.3930.16
      HEALTHCARE PROVIDERS35.8548.563.2182.62108.32142.47187.96248.77330.3131.73
      MEDICAL DEVICE/ EQUIPMENT COMPANIES7.039.3411.9515.3519.7625.5233.0742.9956.0629.37
      OTHER END USERS1.692.262.93.724.786.157.9310.2213.1828.71
      PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES18.5124.9432.3842.1555.0572.1194.76124.92165.231.21
      TOTAL76.24102.65133.1173.12225.85295.56388.01510.98675.0831.08

      Target Audience

      • Healthcare Technology Companies : Develop and commercialize AI oncology solutions tailored to French healthcare requirements, regulatory standards, and hospital procurement processes for market penetration.
      • Pharmaceutical & Medical Device Firms : Integrate AI capabilities into oncology portfolios and identify partnership opportunities with French healthcare providers to enhance diagnostic and treatment offerings.
      • Hospital & Healthcare Systems : Evaluate AI solution investments for cancer care departments, understand market trends, and benchmark against peers to optimize patient outcomes and operational efficiency.
      • Investment & Private Equity Firms : Identify high-growth investment opportunities in France's AI oncology sector with detailed market sizing, growth projections, and competitive analysis for portfolio decisions.
      • Government & Healthcare Policy Makers : Develop evidence-based policies supporting AI adoption in oncology, allocate healthcare budgets effectively, and understand market dynamics for strategic healthcare planning.

      Reasons to Buy this Report

      • Market Size & Growth Data : Access precise valuation metrics for France's AI oncology market with detailed CAGR analysis, enabling accurate financial forecasting and investment decision-making for the 2024-2029 period.
      • Competitive Landscape Intelligence : Understand France-specific market dynamics, key players, and competitive positioning to identify partnership opportunities and market entry strategies in this high-growth healthcare segment.
      • Regulatory & Reimbursement Insights : Gain comprehensive understanding of French healthcare regulations, reimbursement policies, and government initiatives supporting AI adoption in oncology for compliant market operations.
      • Technology Adoption Trends : Identify which AI applications (diagnostic imaging, treatment planning, patient management) are gaining traction in French hospitals and healthcare systems for targeted product development.
      • Strategic Investment Guidance : Make informed investment and expansion decisions with France-specific market forecasts, growth drivers, and emerging opportunities in the rapidly expanding oncology AI sector.

      Frequently asked questions

      What is the current size of France's AI in Oncology market?

      France's AI in Oncology market was valued at $133.1 million in 2024 and is expected to grow significantly through 2029.

      What is the projected market size for AI in Oncology in France by 2029?

      France's AI in Oncology market is forecasted to reach $675.1 million by 2029, growing at a compound annual growth rate of 31.1%.

      What factors are driving AI adoption in France's oncology sector?

      France's adoption is driven by government support for digital health, investment in research infrastructure, regulatory frameworks favoring innovation, and collaboration between academic medical centers and technology providers.

      How does France's AI in Oncology market compare to other European markets?

      France's 31.1% CAGR positions it as a high-growth market within Europe, supported by its centralized healthcare system and strong emphasis on precision medicine and digital transformation.

      Which AI applications are most prevalent in France's oncology market?

      France is seeing significant adoption of AI-powered diagnostic imaging, predictive analytics for treatment planning, patient risk stratification, and clinical decision support systems across major cancer centers.

      RESEARCH METHODOLOGY

      The study involved significant activities to estimate the current size of the AI in oncology. Exhaustive secondary research was done to collect information on the AI in oncology market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in oncology market.

      Secondary Research

      This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in oncology solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

      Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in oncology vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

      Primary Research

      In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the AI in oncology market.

      After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of AI in oncology solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.

      In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

      Breakdown of Primary Participants:

      AI in Oncology Market

      Note 1: Others include sales managers, marketing managers, and product managers.

      Note 2: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in oncology. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • The key players in the industry and markets have been identified through extensive secondary research.
      • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
      AI in Oncology Market

      Data Triangulation

      After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      AI I in oncology is the utilization of AI tools such as machine learning, natural language processing, and computer vision, among others to analyze genomic data and large gene mutations that are unique to an individual’s cancer profile. These AI tools are adopted by various end-users including labs, research centers, hospitals, and biotechnology & pharmaceuticals, among others to address the global cancer burden and the need for precision medicine in oncology.

      Further, AI boosts the speed and accuracy of cancer diagnosis and screening. The major developments include:

      • Pathologists can detect malignancy in prostate biopsy photos with the help of FDA-approved AI software.
      • AI quickly analyzes medical pictures, such as mammograms, increasing radiologists' productivity and enhancing risk assessment and detection of breast cancer.
      • Deep learning is used by NCI scientists to automatically detect precancerous cervical lesions as part of their efforts to improve cervical and prostate cancer screening.

      Stakeholders

      • Clinical/Physician Centers
      • AI Providers
      • Clinical Research Organizations
      • Pharmaceutical/Biopharmaceutical Companies
      • Research and Development (R&D) Companies
      • Business Research and Consulting Service Providers
      • Medical Research Laboratories
      • Academic Medical Centers/Universities/Hospitals
      • Government Agencies
      • Regulatory Agencies
      • Clinical Researchers
      • Clinical Research Organizations
      • Accountable Care Organizations
      • Investors and Venture Capitalists

      Report Objectives

      • To define, describe, and forecast the AI in oncology market based on player type, application, cancer type, technology, deployment model, end user, and region
      • To provide detailed information about the major factors (drivers, opportunities, restraints, and challenges) influencing the growth of the market
      • To analyze opportunities for stakeholders by identifying the high-growth segments of the market
      • To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
      • To analyze subsegments of the market with respect to individual growth trends, prospects, and contributions to the overall market
      • To profile the key players and comprehensively analyze their market sizes and core competencies
      • To track and analyze competitive developments such as acquisitions, collaborations, agreements, mergers, product launches & updates, partnerships, expansions, and other recent developments in the market globally

      Get the Full AI in Oncology Market Report

      Full forecast, segment splits, and company analysis for all AI in Oncology Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status